Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1979 Nov;76(11):5825–5828. doi: 10.1073/pnas.76.11.5825

Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis.

M A Catalano, D A Carson, S F Slovin, D D Richman, J H Vaughan
PMCID: PMC411744  PMID: 230491

Abstract

Prior studies have shown that patients with seropositive rheumatoid arthritis (RA) have an increased frequency of precipitating antibody against a nuclear antigen, the RA nuclear antigen, detected in human B lymphoblastoid cell lines infected by Epstein-Barr virus. The present investigations demonstrate that patients with seropositive RA also have specifically elevated titers of antibodies to another, better-characterized Epstein-Barr virus-associated B cell antigen, the Epstein-Barr nuclear antigen, which is detected by anti-complement immunofluorescence. Titers of these two antibodies were not affected by absorption of rheumatoid factor from serum. Furthermore, patients with RA did not have elevated titers of antibodies against the Epstein-Barr virus capsid antigen or to three other species of human herpesviruses: herpes simplex type 1, varicella-zoster virus, and cytomegalovirus. In both normal individuals and RA patients there was a significant association between the presence of antibodies to RA nuclear antigen and the titers of antibody to Epstein-Barr nuclear antigen. Thus, normal subjects with antibody to RA nuclear antigen had titers of antibody to Epstein-Barr nuclear antigen equivalent to those of patients with RA and significantly higher than normal subjects lacking antibody to RA nuclear antigen. One interpretation of these results is that patients with seropositive RA derive from a larger population with enhanced immune responsiveness to B lymphocyte nuclear antigens determined by the Epstein-Barr virus.

Full text

PDF
5825

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alspaugh M. A., Jensen F. C., Rabin H., Tan E. M. Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J Exp Med. 1978 Apr 1;147(4):1018–1027. doi: 10.1084/jem.147.4.1018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alspaugh M. A., Tan E. M. Antibodies to cellular antigens in Sjögren's syndrome. J Clin Invest. 1975 May;55(5):1067–1073. doi: 10.1172/JCI108007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baron D., Strominger J. L. Partial purification and properties of the Epstein-Barr virus-associated nuclear antigen. J Biol Chem. 1978 Apr 25;253(8):2875–2881. [PubMed] [Google Scholar]
  4. Cohen A. S., Canoso J. J. Criteria for the classification of systemic lupus erythematosus--status 1972. Arthritis Rheum. 1972 Sep-Oct;15(5):540–543. doi: 10.1002/art.1780150512. [DOI] [PubMed] [Google Scholar]
  5. Cremer N. E., Hurwitz D., Quismorio F. P., Lennette E. H., Friou G. J. Antiviral antibodies in rheumatoid synovial fluid and cryoprecipitates. Clin Exp Immunol. 1974 Sep;18(1):27–37. [PMC free article] [PubMed] [Google Scholar]
  6. Elson C. J., Crawford D. H., Bucknall R. C., Allen C., Thompson J. L., Epstein M. A., Hall N. D., Bacon P. A. Infection with E.B. virus and rheumatoid arthritis. Lancet. 1979 Jan;1(8107):105–105. doi: 10.1016/s0140-6736(79)90096-5. [DOI] [PubMed] [Google Scholar]
  7. Epstein M. A., Achong B. G. Recent progress in Epstein-Barr virus research. Annu Rev Microbiol. 1977;31:421–445. doi: 10.1146/annurev.mi.31.100177.002225. [DOI] [PubMed] [Google Scholar]
  8. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaplan J., Shope T. C., Peterson W. D., Jr Epstein-barr virus-negative human malignant T-cell lines. J Exp Med. 1974 May 1;139(5):1070–1076. doi: 10.1084/jem.139.5.1070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Phillips P. E., Waxman J., Hirshaut Y., Kaplan M. H. Virus antibody levels and delayed hypersensitivity in rheumatoid arthritis. Ann Rheum Dis. 1976 Apr;35(2):152–154. doi: 10.1136/ard.35.2.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  12. Schmitz H., Kampa D., Heidenreich W. Sensitive method to detect non-complement-fixing antibodies to Epstein-Barr virus nuclear antigne. Int J Cancer. 1975 Dec 15;16(6):1030–1034. doi: 10.1002/ijc.2910160617. [DOI] [PubMed] [Google Scholar]
  13. Slaughter L., Carson D. A., Jensen F. C., Holbrook T. L., Vaughan J. H. In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. J Exp Med. 1978 Nov 1;148(5):1429–1434. doi: 10.1084/jem.148.5.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Stalder H., Oxman M. N., Herrmann K. L. Herpes simplex virus microneutralization: a simplification of the test. J Infect Dis. 1975 Apr;131(4):423–430. doi: 10.1093/infdis/131.4.423. [DOI] [PubMed] [Google Scholar]
  15. Stanford F. Virus antibody in synovial fluid of rheumatoid and control patients. Ann Rheum Dis. 1974 Jul;33(4):342–345. doi: 10.1136/ard.33.4.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stevens D. A., Stevens M. B., Newell G. R., Levine P. H., Waggoner D. E. Epstein-Barr virus (herpes-type virus) antibodies in connective tissue diseases. Arch Intern Med. 1972 Jul;130(1):23–28. [PubMed] [Google Scholar]
  17. Wilkes R. M., Simsarian J. P., Hopps H. E., Roth H., Decker J. L., Aptekar R. G., Meyer H. M., Jr Virologic studies on rheumatoid arthritis. Arthritis Rheum. 1973 Jul-Aug;16(4):446–454. doi: 10.1002/art.1780160403. [DOI] [PubMed] [Google Scholar]
  18. Zaia J. A., Oxman M. N. Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells. J Infect Dis. 1977 Oct;136(4):519–530. doi: 10.1093/infdis/136.4.519. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES